Related Experiment Video

Updated: Aug 19, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

588

Platelet CD36 links overweight and a prothrombotic phenotype in patients with non-valvular atrial fibrillation

Hua Wang1, Wei-Hong Yan1, Lei Gong2

  • 1Department of Cardiology, Yantai Yuhuangding Hospital, Qingdao Medical College, Qingdao University, Yantai, China.

Frontiers in Cardiovascular Medicine
|December 5, 2022
PubMed

Insights

Platelet CD36 may link overweight and increased clotting risk in non-valvular atrial fibrillation (NVAF). Targeting platelet CD36 could help prevent prothrombotic states in overweight NVAF patients.

Area of Science:

  • Cardiology
  • Hematology
  • Metabolic Disorders

Background:

  • Overweight is linked to a prothrombotic state in non-valvular atrial fibrillation (NVAF), but mechanisms are unclear.
  • Understanding these links is crucial for stroke risk management in NVAF patients.

Purpose of the Study:

  • To investigate the role of platelet CD36 in the association between overweight and stroke risk in NVAF patients.
  • To evaluate platelet CD36 expression and its correlation with body mass index (BMI) and platelet activation.

Main Methods:

  • A cross-sectional study included 182 NVAF patients, categorized into normal weight and overweight groups.
  • Clinical, echocardiographic, and biochemical data were collected.
  • Platelet CD36 and integrin αIIbβ3 expression were measured using flow cytometry.

Main Results:

  • Overweight patients (62.64%) showed significantly higher BMI, cholesterol, triglycerides, and left atrium dimensions.
  • Platelet CD36 expression was significantly elevated in overweight patients, correlating positively with BMI and platelet activation markers.
  • Platelet CD36 and BMI were identified as independent risk factors for platelet activation in NVAF.

Conclusions:

  • Platelet CD36 appears to mediate the relationship between overweight and platelet hyperactivity in NVAF.
  • Targeting platelet CD36 may offer a novel strategy to mitigate the prothrombotic state in overweight NVAF patients.
Abstract

Keywords:
non-valvular atrial fibrillationoverweightplatelet CD36platelet activationstroke

More Related Videos

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial08:14

Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial

Published on: September 29, 2015

13.0K
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.0K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
827
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
585
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.8K
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K